Johnson & Johnson
JNJ,
-0.28%
stated Wednesday its one-dose COVID-19 vaccine has been granted full approval by Well being Canada, marking its first main regulatory approval. The vaccine has been granted an emergency use authorization within the U.S. Up to now, solely the vaccine developed by Pfizer Inc.
PFE,
-0.37%
and German associate BioNTech SE
BNTX,
-1.32%
has gained full approval from the U.S. regulator, the Meals and Drug Administration, in an August resolution. A full approval permits the vaccine to be mandated by corporations and establishments and consultants have been hopeful it will assist persuade unvaccinated people who the vaccine is protected and efficient. “As vaccination charges proceed to climb, a vaccine that stops extreme illness and protects towards COVID-related hospitalization and demise will assist ease the pressure on healthcare programs and is a crucial possibility for folks in Canada and world wide,” stated Mathai Mammen, M.D., Ph.D., world head, Janssen Analysis & Growth, Johnson & Johnson, in a press release. J&J shares have been barely decrease premarket, however have gained 2% within the yr thus far, whereas the Dow Jones Industrial Common
DJIA,
-0.03%
has gained 17% and the S&P 500
SPX,
+0.23%
has gained 25%.

Source link